用于检测和定量JAK2（V617F）的全血与纯化血粒细胞的比较。 - Suppr

Suppr

超能文献

Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F).

作者信息

Hermouet S, Dobo I, Lippert E, Boursier M-C, Ergand L, Perrault-Hu F, Pineau D

出版信息

Leukemia. 2007 May;21(5):1128-30. doi: 10.1038/sj.leu.2404588. Epub 2007 Feb 15.

DOI:10.1038/sj.leu.2404588

PMID:17301814

Abstract

摘要

相似文献

Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F).

Leukemia. 2007 May;21(5):1128-30. doi: 10.1038/sj.leu.2404588. Epub 2007 Feb 15.

Plasma quantitation of JAK2 mutation is not suitable as a clinical test: an artifact of storage.

Blood. 2009 Jul 2;114(1):223-4; author reply 224. doi: 10.1182/blood-2009-03-209593.

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.

Cancer. 2006 Nov 1;107(9):2206-11. doi: 10.1002/cncr.22240.

JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.

Br J Haematol. 2007 Oct;139(1):64-9. doi: 10.1111/j.1365-2141.2007.06755.x.

Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders.

Intern Med J. 2008 Jun;38(6):422-6. doi: 10.1111/j.1445-5994.2007.01589.x. Epub 2008 Mar 7.

Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders.

J Mol Diagn. 2007 Apr;9(2):272-6. doi: 10.2353/jmoldx.2007.060133.

Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes.

Br J Haematol. 2005 Sep;130(5):797-9. doi: 10.1111/j.1365-2141.2005.05682.x.

Comparison of JAK2 V617F burden quantitation by two different quantitative-polymerase chain reaction methods.

Int J Lab Hematol. 2010 Aug 1;32(4):458-60. doi: 10.1111/j.1751-553X.2010.01209.x. Epub 2010 Mar 23.

JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.

Coll Antropol. 2012 Sep;36(3):859-65.

What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?

Lab Hematol. 2011 Mar;17(1):12-6. doi: 10.1532/LH96.10018.

引用本文的文献

CRISPR/Cas12a-Based Ultrasensitive and Rapid Detection of V617F Somatic Mutation in Myeloproliferative Neoplasms.

Biosensors (Basel). 2021 Jul 24;11(8):247. doi: 10.3390/bios11080247.

International external quality assurance of JAK2 V617F quantification.

Ann Hematol. 2019 May;98(5):1111-1118. doi: 10.1007/s00277-018-3570-8. Epub 2018 Dec 8.

Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts.

PLoS One. 2013;8(2):e57856. doi: 10.1371/journal.pone.0057856. Epub 2013 Feb 28.

A real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2V617F mutation using a locked nucleic acid-modified oligonucleotide.

J Mol Diagn. 2010 Jul;12(4):512-9. doi: 10.2353/jmoldx.2010.090137. Epub 2010 Apr 29.

Quantitative assay for the detection of the V617F variant in the Janus kinase 2 (JAK2) gene using the Luminex xMAP technology.

BMC Med Genet. 2010 Apr 1;11:54. doi: 10.1186/1471-2350-11-54.

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.

Haematologica. 2009 Jan;94(1):38-45. doi: 10.3324/haematol.13486. Epub 2008 Nov 10.

A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.

J Mol Diagn. 2008 Sep;10(5):435-41. doi: 10.2353/jmoldx.2008.080015. Epub 2008 Jul 31.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验